PMID- 26091383
OWN - NLM
STAT- MEDLINE
DCOM- 20160408
LR  - 20150620
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 14
IP  - 6
DP  - 2015 Jun
TI  - Efficacy and Safety of Subantimicrobial Dose, Modified-Release Doxycycline 40 mg 
      Versus Doxycycline 100 mg Versus Placebo for the treatment of Inflammatory 
      Lesions in Moderate and Severe Acne: A Randomized, Double-Blinded, Controlled 
      Study.
PG  - 581-6
AB  - INTRODUCTION: Routine use of doxycycline (DC) 100 mg for the treatment of 
      moderate to severe acne may be associated with gastrointestinal adverse events 
      (AEs), thus potentially impacting patient adherence, and antibiotic resistance. 
      This study evaluated the safety and efficacy of subantimicrobial, 
      modified-release (MR) DC 40 mg compared to DC 100 mg and to placebo for the 
      treatment of inflammatory lesions in moderate and severe acne. METHODS: 662 
      subjects aged 12 years or older with moderate to severe acne received 
      subantimicrobial, MR-DC 40 mg tablets, DC 100 mg capsules, or placebo once daily 
      for 16 weeks. RESULTS: MR-DC 40 mg was superior to placebo in the mean reduction 
      of the number of inflammatory lesions, median percent reduction in inflammatory 
      and total lesions, and success rate. MR-DC 40 mg was also comparable to DC 100 mg 
      in the reduction of the number of inflammatory lesions, and percent reduction of 
      total lesions. Incidence of drug-related AEs for MR-DC 40 mg was similar to 
      placebo and was markedly smaller compared to DC 100 mg. DISCUSSION: MR-DC 40 mg 
      demonstrated comparable efficacy and superior safety to DC 100 mg in the 
      treatment of moderate to severe inflammatory acne.
FAU - Moore, Angela
AU  - Moore A
FAU - Ling, Mark
AU  - Ling M
FAU - Bucko, Alicia
AU  - Bucko A
FAU - Manna, Vasant
AU  - Manna V
FAU - Rueda, Marie-Jose
AU  - Rueda MJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - N12000U13O (Doxycycline)
SB  - IM
MH  - Acne Vulgaris/*drug therapy
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Infective Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Child
MH  - Delayed-Action Preparations
MH  - Double-Blind Method
MH  - Doxycycline/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2015/06/20 06:00
MHDA- 2016/04/09 06:00
CRDT- 2015/06/20 06:00
PHST- 2015/06/20 06:00 [entrez]
PHST- 2015/06/20 06:00 [pubmed]
PHST- 2016/04/09 06:00 [medline]
AID - S1545961615P0581X [pii]
PST - ppublish
SO  - J Drugs Dermatol. 2015 Jun;14(6):581-6.